Goldman's Cecil Medicine, 24th Edition

2.1. Patient Enrolment. We performed an open-label clinical studyin the Department of Neurology, Sun Yat-sen Memorial Hospital. The study wasapproved by the Ethics Committee of Sun Yat-sen Memorial Hospital, SunYat-sen University (Guangzhou, China). Part of the study has been registeredin the Chinese Clinical Trial Registry (registration number:ChiCTR-INR-16008908). The inclusion criteria used for the study were asfollows: (1) a neurological disease diagnosis that met the diagnosticcriteria of Goldman's Cecil Medicine 24th edition [13] and (2)willingness of the patient and his/her family to sign an informed consentform and good compliance with examination, treatment, and follow-up. Theexclusion criteria used for the study were as follows: (1) inflammatory orautoimmune diseases within half a year before recruitment (such as infectiousdiseases, systemic lupus erythematosus, rheumatoid or rheumatic disease, orthyroid disease); (2) glucocorticoid, immunosuppressant, or gamma globulinuse within 15 days; (3) nosocomial infection; (4) a severe medical condition,such as cerebral hernia, status epilepticus, single or multiple organfailure, or unstable vital signs; (5) acute myocardial infarction; (6)hematologic disorders; (7) tumour; (8) pregnant or lactating women; (9)allergy to local anaesthetic; and (10) current participation in anotherclinical trial or participation in another clinical trial within 30 days.

Goldman's Cecil Medicine, 24th Edition

041b061a72